Riker's Tambocor (flecainide)
According to FDA minutes of its Cardio-Renal Drugs Advisory Cmte. meeting in June, the cmte. recommended approval of Tambocor for use in "symptomatic ventricular arrhythmias" rather than "symptomatic sustained ventricular tachycardia" as reported ("The Pink Sheet" June 25, p. 12).
You may also be interested in...
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.